Lynparza plus abi/pred approved in Japan for treatment of prostate cancer
First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent
First PARP inhibitor approved in Japan to demonstrate clinically meaningful benefits in combination with a new hormonal agent
Subscribe To Our Newsletter & Stay Updated